IL270326A - - Google Patents

Info

Publication number
IL270326A
IL270326A IL27032619A IL27032619A IL270326A IL 270326 A IL270326 A IL 270326A IL 27032619 A IL27032619 A IL 27032619A IL 27032619 A IL27032619 A IL 27032619A IL 270326 A IL270326 A IL 270326A
Authority
IL
Israel
Application number
IL27032619A
Other languages
English (en)
Other versions
IL270326B (en
IL270326B2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/048748 external-priority patent/WO2018039642A1/en
Publication of IL270326A publication Critical patent/IL270326A/en
Application filed filed Critical
Publication of IL270326B publication Critical patent/IL270326B/en
Publication of IL270326B2 publication Critical patent/IL270326B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL270326A 2017-05-04 2019-10-31 Tdr with new preparations, combinations and their methods IL270326B2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762501696P 2017-05-04 2017-05-04
PCT/US2017/048748 WO2018039642A1 (en) 2016-08-26 2017-08-25 Compositions and methods thereof
TW106129169A TW201815387A (zh) 2016-08-26 2017-08-28 組成物及其方法
US201862634162P 2018-02-22 2018-02-22
US201862636099P 2018-02-27 2018-02-27
US201862635554P 2018-02-27 2018-02-27
US201862636171P 2018-02-28 2018-02-28
PCT/US2018/030978 WO2018204713A1 (en) 2017-05-04 2018-05-03 Targeted drug rescue with novel compositions, combinations, and methods thereof

Publications (3)

Publication Number Publication Date
IL270326A true IL270326A (https=) 2018-05-03
IL270326B IL270326B (en) 2022-10-01
IL270326B2 IL270326B2 (en) 2023-02-01

Family

ID=65431106

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270326A IL270326B2 (en) 2017-05-04 2019-10-31 Tdr with new preparations, combinations and their methods

Country Status (13)

Country Link
EP (1) EP3618819A4 (https=)
JP (2) JP7514078B2 (https=)
KR (2) KR20200062078A (https=)
CN (1) CN110831584B (https=)
AU (2) AU2018261654A1 (https=)
BR (1) BR112019022902A2 (https=)
CA (2) CA3062452C (https=)
IL (1) IL270326B2 (https=)
MA (1) MA49464A (https=)
RU (1) RU2760558C9 (https=)
TW (1) TWI787260B (https=)
WO (1) WO2018204713A1 (https=)
ZA (1) ZA201908006B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113825510A (zh) * 2019-03-18 2021-12-21 阿瓦尼尔制药股份有限公司 使用氘化右美沙芬和奎尼丁治疗精神分裂症的阴性症状的方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110831584B (zh) * 2017-05-04 2023-03-10 埃克塞瓦有限责任公司 具有新颖的组合物、组合的靶向药物拯救及其方法
JP7400818B2 (ja) * 2019-06-06 2023-12-19 Jsr株式会社 感放射線性樹脂組成物、レジストパターン形成方法及び化合物
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
CN116473073A (zh) * 2023-05-08 2023-07-25 广东方中高新材料有限公司 一种含镓配合物的吡唑醚菌酯增效悬浮制剂及其制备方法
CN116473077B (zh) * 2023-05-08 2025-04-11 广东方中高新材料有限公司 一种n,n配位的镓配合物抗菌剂的合成和应用
CN119432479B (zh) * 2023-08-04 2025-10-03 中国石油天然气股份有限公司 柴油机润滑油组合物及其制备方法
CN120987847B (zh) * 2024-11-29 2026-02-17 江苏恩华药业股份有限公司 一种氢溴酸右美沙芬的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241065A (en) * 1979-07-02 1980-12-23 E. I. Du Pont De Nemours And Company Fluoro analogs of hydrocodone and oxycodone useful as analgesics, narcotic antagonists or both
US4950658A (en) * 1988-12-06 1990-08-21 Board Of Trustees Of Southern Illinois Univ. Method of medical treatment of Alzheimer's disease
US5891885A (en) 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6207674B1 (en) 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
TWI326214B (en) 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
EP1986639A4 (en) 2006-02-03 2010-04-28 Avanir Pharmaceuticals PHARMACEUTICAL COMPOSITIONS OF DEXTROMETHORPHANE AND CHINIDINE FOR THE TREATMENT OF DEPRESSION, FEAR STATES AND NEURODEEGENERATIVE DISEASES
MX370608B (es) * 2007-05-01 2019-12-18 Concert Pharmaceuticals Inc Compuestos de morfinano.
JP5466147B2 (ja) * 2007-05-21 2014-04-09 レビバ ファーマシューティカルズ,インコーポレーテッド キノリノン系非定型抗精神病薬剤の組成物、合成、及び使用方法
US8017623B2 (en) * 2008-07-03 2011-09-13 Trinity Laboratories, Inc. Dextromethorphan hydrochloride
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
WO2014138669A1 (en) * 2013-03-07 2014-09-12 Mindlab LLC Pain medicine combination and uses thereof
EP2972329A2 (en) 2013-03-15 2016-01-20 Kinemed, Inc. Biomarkers
MY198587A (en) * 2014-09-14 2023-09-06 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
US11103499B2 (en) * 2016-08-26 2021-08-31 EXCIVA (UG) (haftungsbeschränkt) Compositions and methods thereof
CN110831584B (zh) * 2017-05-04 2023-03-10 埃克塞瓦有限责任公司 具有新颖的组合物、组合的靶向药物拯救及其方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113825510A (zh) * 2019-03-18 2021-12-21 阿瓦尼尔制药股份有限公司 使用氘化右美沙芬和奎尼丁治疗精神分裂症的阴性症状的方法

Also Published As

Publication number Publication date
CN110831584B (zh) 2023-03-10
TWI787260B (zh) 2022-12-21
JP7514078B2 (ja) 2024-07-10
KR102444803B1 (ko) 2022-09-19
JP2020518617A (ja) 2020-06-25
RU2760558C2 (ru) 2021-11-29
CA3062452C (en) 2023-10-24
TW201842902A (zh) 2018-12-16
KR20200062078A (ko) 2020-06-03
EP3618819A1 (en) 2020-03-11
RU2760558C9 (ru) 2022-02-22
AU2018261654A1 (en) 2019-11-14
MA49464A (fr) 2020-04-29
KR20210130827A (ko) 2021-11-01
JP2023143940A (ja) 2023-10-06
CN110831584A (zh) 2020-02-21
EP3618819A4 (en) 2021-01-20
RU2019137004A (ru) 2021-06-04
CA3138116A1 (en) 2018-11-08
IL270326B (en) 2022-10-01
AU2021215274B2 (en) 2022-11-03
BR112019022902A2 (pt) 2020-05-19
CA3062452A1 (en) 2018-11-08
RU2019137004A3 (https=) 2021-06-04
IL270326B2 (en) 2023-02-01
WO2018204713A1 (en) 2018-11-08
ZA201908006B (en) 2021-04-28
AU2021215274A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
BR122021024397A2 (https=)
BR122021000189A2 (https=)
BR112019008823A2 (https=)
RU2019137004A3 (https=)
BR112020006084A8 (https=)
BR122022025811B8 (https=)
BR202018014992U2 (https=)
BR122021023687A2 (https=)
BR122021014832A2 (https=)
BR122022003518A2 (https=)
BR112020008820A2 (https=)
BR202017025154U2 (https=)
BR102017023327A2 (https=)
BR202017021228U2 (https=)
BR202017020981U2 (https=)
BE2017C035I2 (https=)
BR202017017068U2 (https=)
BR202017016984U2 (https=)
BR202017016924U2 (https=)
BR102017015495A2 (https=)
BR102017015250A2 (https=)
BR102017014430A2 (https=)
BR202017012548U2 (https=)
BR202017011220U2 (https=)
BR202017010814U2 (https=)